共 50 条
- [21] EFFICACY AND SAFETY RESULTS 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) VS CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB)GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1195Lampertico, PietroButi, MariaFung, ScottAhn, Sang HoonChuang, Wan-LongTak, Won YoungRamji, AlnoorChen, Chi-YiTam, EdwardBae, HoMa, XiaoliFlaherty, John F.Gaggar, AnujLau, Audrey H.Feierbach, BecketWu, GeorgeSuri, VithikaSubramanian, ManiTrinh, Huy N.Yoon, Seung-KewAgarwal, KoshLim, Young-SukChan, Henry L.
- [22] A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Week 48 Efficacy and Safety ResultsSWISS MEDICAL WEEKLY, 2019, : 25S - 25SLampertico, PietroButi, MariaFung, ScottAhn, Sang HoonChuang, Wan-LongTak, Won YoungRamji, AlnoorChen, Chi-YiTam, EdwardBae, HoMa, XiaoliFlaherty, John F.Gaggar, AnujLau, AudreyFeierbach, BecketWu, GeorgeSuri, VithikaSubramanian, G. ManiOberle, CorinnaHuy TrinhYoon, Seung-KewAgarwal, KoshLim, Young-SukChan, Henry L. Y.
- [23] IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAFHEPATOLOGY, 2020, 72 : 484A - 484AKao, Jia-HorngChuang, Wan-LongChen, Chi-YiAhn, Sang HoonFung, Scott K.Elkhashab, MagdyHann, Hie-Won L.Ravendhran, NatarajanNguyen, Tuan T.Tan, SusannaFlaherty, John F.Gagger, AnujGao, BingBrainard, Diana M.Phan, Charles G.Lim, Young-SukFerret, Maria Asuncion ButiLampertico, Pietro
- [24] NO DETECTED RESISTANCE TO TENOFOVIR ALAFENAMIDE (TAF) TREATMENT IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B (CHB): RESULTS FROM WEEK 24 PRIMARY ENDPOINT ANALYSISHEPATOLOGY, 2022, 76 : S255 - S256Schwarz, Kathleen B.Bezerra, Jorge A.Liu, YangHan, DongXu, SiminYazdi, TahminehMay, LindseyChang, SilviaMartin, RossMo, HongmeiAbramov, FridaFlaherty, John F.Rosenthal, PhilipChang, Mei-Hwei
- [25] EFFECTIVENESS AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE FUMARATE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B VIRUS INFECTED PATIENTS WITH OSTEOPOROSIS RISK: 24 WEEKS AND 48weeks RESULTS OF A REAL-WORLD STUDYHEPATOLOGY, 2021, 74 : 478A - 478ALi, HuiWei, JiaLi, ChunmeiLiu, YunhuaWang, HongyanLuo, XinghuaGong, Ming
- [26] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety resultsJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 82 - 82Strasser, S.Roberts, S.Angus, P.Chan, H. L. Y.Fung, S.Seto, W. K.Chuang, W. L.Chen, C. Y.Kim, H. J.Hui, A. J.Janssen, H. L. A.Chowdhury, A.Tsang, T. Y. O.Mehta, R.Gane, E.Flaherty, J. F.Massetto, B.Kitrinos, K.Dinh, P.Subramanian, G. M.Mchutchison, J. G.Lim, Y. S.Acharya, S. K.Agarwal, K.
- [27] A Phase 3 Study Comparing Switching: Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 ResultsAMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S543 - S543Khalili, MandanaLampertico, PietroBae, Ho S.Ma, XiaoliRamji, AlnoorFung, ScottAhn, Sang HoonKao, Jia-HorngTam, EdwardHalton, PatriciaYee, LelandFlaherty, JohnGaggar, AnujLiu, YangWu, GeorgeHann, Hie-WonAgarwal, KoshLim, Young-SukButi, MariaChan, Henry
- [28] SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT, OR WITH END-STAGE RENAL DISEASE (ESRD)GUT, 2021, 70 : A76 - A77La Janssen, HarryLampertico, PietroChen, Chien-HungHeo, JeongFournier, ClaireAhn, Sang HoonTsang, Tak Yin OwenCoffin, Carla S.Huang, HsangMarchesini, GiulioHui, Aric JosunElkhashab, MagdyJafri, Sayed-MohammedChan, Carol Yee KwanTan, Susanna K.Zhao, YangSuri, VithikaFlaherty, John F.Gaggar, AnujBrainard, DianaChuang, Wan-LongAgarwal, KoshGane, EdwardLim, Young-Suk
- [29] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE AFTER SWITCHING FROM ENTECAVIR IN PATIENTS WITH CHRONIC HEPATITIS BHEPATOLOGY, 2021, 74 : 480A - 480AHann, Hie-Won L.Park, GraceBin Park, KyongJuon, Hee-Soon
- [30] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trialHIV MEDICINE, 2020, 21 : 17 - 17Maggiolo, F.Rizzardini, G.Molina, J. M.Pulido, F.DeWit, S.Vandekerckhove, L.Berenguer, J.D'Antoni, M.Blair, C.Chuck, S.Piontkowsky, D.Martin, H.McNicholl, I.Payne, B.Gallant, J.